EyePoint Pharmaceuticals (EYPT) Misses Q3 EPS by 8c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.85), $0.08 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $966 thousand versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nutrien warns shareholders about below-market mini-tender offer
• Nvidia pitches Vera CPU to Chinese clients with August delivery target